215 related articles for article (PubMed ID: 12586806)
1. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial.
Carducci MA; Padley RJ; Breul J; Vogelzang NJ; Zonnenberg BA; Daliani DD; Schulman CC; Nabulsi AA; Humerickhouse RA; Weinberg MA; Schmitt JL; Nelson JB
J Clin Oncol; 2003 Feb; 21(4):679-89. PubMed ID: 12586806
[TBL] [Abstract][Full Text] [Related]
2. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan.
Nelson JB; Nabulsi AA; Vogelzang NJ; Breul J; Zonnenberg BA; Daliani DD; Schulman CC; Carducci MA
J Urol; 2003 Mar; 169(3):1143-9. PubMed ID: 12576870
[TBL] [Abstract][Full Text] [Related]
3. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.
Carducci MA; Saad F; Abrahamsson PA; Dearnaley DP; Schulman CC; North SA; Sleep DJ; Isaacson JD; Nelson JB;
Cancer; 2007 Nov; 110(9):1959-66. PubMed ID: 17886253
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
[TBL] [Abstract][Full Text] [Related]
5. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics.
Carducci MA; Nelson JB; Bowling MK; Rogers T; Eisenberger MA; Sinibaldi V; Donehower R; Leahy TL; Carr RA; Isaacson JD; Janus TJ; Andre A; Hosmane BS; Padley RJ
J Clin Oncol; 2002 Apr; 20(8):2171-80. PubMed ID: 11956279
[TBL] [Abstract][Full Text] [Related]
6. Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer.
Zonnenberg BA; Groenewegen G; Janus TJ; Leahy TW; Humerickhouse RA; Isaacson JD; Carr RA; Voest E
Clin Cancer Res; 2003 Aug; 9(8):2965-72. PubMed ID: 12912943
[TBL] [Abstract][Full Text] [Related]
7. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer.
Nelson JB; Love W; Chin JL; Saad F; Schulman CC; Sleep DJ; Qian J; Steinberg J; Carducci M;
Cancer; 2008 Nov; 113(9):2478-87. PubMed ID: 18785254
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer.
Michaelson MD; Kaufman DS; Kantoff P; Oh WK; Smith MR
Cancer; 2006 Aug; 107(3):530-5. PubMed ID: 16804927
[TBL] [Abstract][Full Text] [Related]
9. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.
Pili R; Häggman M; Stadler WM; Gingrich JR; Assikis VJ; Björk A; Nordle O; Forsberg G; Carducci MA; Armstrong AJ
J Clin Oncol; 2011 Oct; 29(30):4022-8. PubMed ID: 21931019
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.
Quinn DI; Tangen CM; Hussain M; Lara PN; Goldkorn A; Moinpour CM; Garzotto MG; Mack PC; Carducci MA; Monk JP; Twardowski PW; Van Veldhuizen PJ; Agarwal N; Higano CS; Vogelzang NJ; Thompson IM
Lancet Oncol; 2013 Aug; 14(9):893-900. PubMed ID: 23871417
[TBL] [Abstract][Full Text] [Related]
11. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.
Armstrong AJ; Creel P; Turnbull J; Moore C; Jaffe TA; Haley S; Petros W; Yenser S; Gockerman JP; Sleep D; Hurwitz H; George DJ
Clin Cancer Res; 2008 Oct; 14(19):6270-6. PubMed ID: 18829508
[TBL] [Abstract][Full Text] [Related]
12. Atrasentan for metastatic hormone refractory prostate cancer.
Murphy G
Issues Emerg Health Technol; 2005 Dec; (77):1-4. PubMed ID: 16544441
[TBL] [Abstract][Full Text] [Related]
13. Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies.
Ryan CW; Vogelzang NJ; Vokes EE; Kindler HL; Undevia SD; Humerickhouse R; André AK; Wang Q; Carr RA; Ratain MJ
Clin Cancer Res; 2004 Jul; 10(13):4406-11. PubMed ID: 15240529
[TBL] [Abstract][Full Text] [Related]
14. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.
Fizazi K; Higano CS; Nelson JB; Gleave M; Miller K; Morris T; Nathan FE; McIntosh S; Pemberton K; Moul JW
J Clin Oncol; 2013 May; 31(14):1740-7. PubMed ID: 23569308
[TBL] [Abstract][Full Text] [Related]
15. Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics.
Thakkar SG; Choueiri TK; Garcia JA
Curr Oncol Rep; 2006 Mar; 8(2):108-13. PubMed ID: 16507220
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
Canil CM; Moore MJ; Winquist E; Baetz T; Pollak M; Chi KN; Berry S; Ernst DS; Douglas L; Brundage M; Fisher B; McKenna A; Seymour L
J Clin Oncol; 2005 Jan; 23(3):455-60. PubMed ID: 15659491
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial.
Webb DJ; Coll B; Heerspink HJL; Andress D; Pritchett Y; Brennan JJ; Houser M; Correa-Rotter R; Kohan D; Makino H; Perkovic V; Remuzzi G; Tobe SW; Toto R; Busch R; Pergola P; Parving HH; de Zeeuw D
Drugs R D; 2017 Sep; 17(3):441-448. PubMed ID: 28831752
[TBL] [Abstract][Full Text] [Related]
18. Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer.
Trump DL; Payne H; Miller K; de Bono JS; Stephenson J; Burris HA; Nathan F; Taboada M; Morris T; Hubner A
Prostate; 2011 Sep; 71(12):1264-75. PubMed ID: 21271613
[TBL] [Abstract][Full Text] [Related]
19. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone.
Nelson JB; Fizazi K; Miller K; Higano C; Moul JW; Akaza H; Morris T; McIntosh S; Pemberton K; Gleave M
Cancer; 2012 Nov; 118(22):5709-18. PubMed ID: 22786751
[TBL] [Abstract][Full Text] [Related]
20. Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer.
Miller K; Moul JW; Gleave M; Fizazi K; Nelson JB; Morris T; Nathan FE; McIntosh S; Pemberton K; Higano CS
Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):187-92. PubMed ID: 23381694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
